Can spironolactone's antiandrogenic effects reduce libido in women?

Spironolactone is widely recognized for its antiandrogenic properties, which form the basis for its use in treating androgen-mediated conditions such as acne and hirsutism. However, these same mechanisms can interfere with sexual health in some women.

Clinical evidence and outcomes

Clinical research confirms that spironolactone significantly impacts androgen levels and sexual function.

• Androgen reduction: In women with conditions like Polycystic Ovary Syndrome (PCOS), spironolactone has been shown to reduce total testosterone levels by approximately 30%.
• Impact on sexual function: Studies utilizing the Female Sexual Function Index (FSFI) demonstrate that lower levels of bioavailable androgens—specifically a lower Free Androgen Index (FAI)—are associated with reduced scores across multiple domains of sexual function. Conversely, elevated levels of sex hormone-binding globulin (SHBG), which further reduces free testosterone, correlate negatively with sexual desire.
• Postmenopausal considerations: In postmenopausal populations, androstenedione levels have been significantly linked to scores for arousal, orgasm, and overall sexual satisfaction. The efficacy of testosterone therapy in treating Hypoactive Sexual Desire Disorder (HSDD) further reinforces the link between androgen signaling and female libido.

Mechanistic explanations

Spironolactone disrupts androgen signaling through two primary pathways:

• Receptor Antagonism: It acts as a competitive antagonist at the androgen receptor (AR). By binding to these receptors, it directly prevents potent androgens like dihydrotestosterone (DHT) from triggering cellular responses.
• Biosynthetic Inhibition: Spironolactone inhibits key enzymes in the cytochrome P450 family involved in androgen biosynthesis. This reduces the systemic production of testosterone and other adrenal steroids.
• Neurological signaling: Androgens facilitate sexual receptivity by interacting with receptors in the ventromedial nucleus of the hypothalamus. By blocking these receptors and lowering hormone availability, spironolactone can dampen the central nervous system signals required for sexual desire.

Bottom line

Spironolactone robustly lowers androgen signaling through direct receptor blockade and inhibited hormone synthesis. Because androgen signaling is a key driver of female sexual desire and arousal, this medication can contribute to reduced libido and sexual dysfunction in some women.